12.09.2014 • NewsGoogleCalicoAbbVie

Google and AbbVie Partner on R&D for Age-related Illnesses

Calico, an investment firm founded by Google to fund projects aimed at delaying the human aging process, is partnering with US drugmaker AbbVie to develop therapies for age-related diseases of the nervous system, such as Parkinson's, as well as cancer.

At the outset of the cooperation, each of the companies will make a financial contribution to the research valued at $250 million. At a later stage, contributions of around $500 million are envisioned, bringing the total to $1.5 billion.

Calico is to be headed by Arthur Levinson, former CEO of biotechnology firm Genentech, now part of Swiss pharmaceutical producer Roche. Levinson has since given up his seat on the Roche board of directors to avoid any potential conflict of interest.

Googl is said to be planning to build a "world-class" research campus for Calico near San Francisco, California.

According to the division of labor within the alliance, Calico will be responsible for basic research and early development of treatment strategies, while Abbevie will conduct clinical trials with patients and market any drugs developed.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.